The LungFX approval gives United Therapeutics control of a centralized donor lung evaluation platform, although clinical warnings, logistics and economics will influence adoption.
Find out how United Therapeutics’ FDA-cleared UHeart trial could reshape xenotransplantation for end-stage heart failure patients.
IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.
A pig-heart trial is no longer just a scientific leap. United Therapeutics now faces the harder test of safety, scale, and regulation.
United Therapeutics’ miroliverELAP showed positive phase 1 safety results in acute liver failure. Find out what this could mean for future liver support strategies.